Despite the well-established differences in PTEN loss and PIK3CA activation, these mutations behave similarly in their response to the two-step therapy, suggesting that tumours carrying either PTEN loss or oncogenic mutations in PIK3CA could benefit from the two-step therapy. This evidence concerns the gene PIK3CA and neoplasm.